Andrew R. Kolarich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andrew R. Kolarich has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Alex J. Solomon
Division of Interventional Radiology, Duke University Health System, Durham, NC, USA
4 shared publications - Christos Georgiades
Department of Vascular & Interventional Radiology, Johns Hopkins University, 1800 Orleans St, Zayed 7203, Baltimore, MD 21287
3 shared publications Constantine Frangakis
Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University Hospital, Baltimore, Maryland
2 shared publications- Ahmet Gurakar
Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication - Alejandro Vera Garcia
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland
1 shared publication - Alice Zhou
University of California San Francisco
1 shared publication
Latest Publications
- 28 June 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 33 (10) , 1222-1229.e1
Radiofrequency Ablation versus Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Awaiting Liver Transplant: An Analysis of the Scientific Registry of Transplant Recipients
- 28 June 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 33 (10) , 1222-1229.e1
Radiofrequency Ablation versus Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Awaiting Liver Transplant: An Analysis of the Scientific Registry of Transplant Recipients
- 1 November 2021
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 41 (7) , 2157-2175
Imaging Manifestations and Interventional Treatments for Hereditary Hemorrhagic Telangiectasia
Hereditary hemorrhagic telangiectasia is an autosomal dominant disorder that causes multisystem vascular malformations, and early diagnosis, screening, and multidisciplinary treatment are important... Hemorrhagic hereditary telangiectasia (HHT) is a rare autosomal dominant disorder that causes multisystem vascular malformations including mucocutaneous telangiectasias and arteriovenous malformati...
- 1 November 2021
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 41 (7) , 2157-2175
Imaging Manifestations and Interventional Treatments for Hereditary Hemorrhagic Telangiectasia
Hereditary hemorrhagic telangiectasia is an autosomal dominant disorder that causes multisystem vascular malformations, and early diagnosis, screening, and multidisciplinary treatment are important... Hemorrhagic hereditary telangiectasia (HHT) is a rare autosomal dominant disorder that causes multisystem vascular malformations including mucocutaneous telangiectasias and arteriovenous malformati...
- 24 August 2021
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 14 (5) , 503-507
Interventional and surgical management of internal jugular venous stenosis: a narrative review
Background A small subset of patients with presumed idiopathic intracranial hypertension are found to have isolated internal jugular vein stenosis (IJVS). Objective To review the current interventions used in patients who present with intracranial hypertension secondary to IJVS. Methods In December 2020, we performed a literature search on Pubmed/Medline and Scopus databases for original articles studying surgical and endovascular interventions used for intracranial hypertension in the setting of internal jugular vein stenosis. No date, patient population, or study type was excluded. Results All studies that included at least one case in which a surgical or endovascular intervention was used to treat IJVS were included. Selection criteria for patients varied, most commonly defined by identification of compression of the internal jugular vein. The 17 studies included in this review ranged from case reports to large single-center cohort studies. The most used surgical intervention was styloidectomy. Styloidectomy had an overall better outcome success rate (79%) than angioplasty/stenting (66%). No complications were recorded in any of the surgical cases analyzed. Outcome measures varied, but all studies recorded clinical symptoms of the patients. Conclusion Few current large cohort studies analyze surgical and endovascular interventions for patients with IJVS. Notably, the most common intervention is styloidectomy, followed by internal jugular vein stenting. By understanding the trends and experience of interventionalists and surgeons, more focused and larger studies can be performed to determine effective strategies with the best clinical outcomes.
- 24 August 2021
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 14 (5) , 503-507
Interventional and surgical management of internal jugular venous stenosis: a narrative review
Background A small subset of patients with presumed idiopathic intracranial hypertension are found to have isolated internal jugular vein stenosis (IJVS). Objective To review the current interventions used in patients who present with intracranial hypertension secondary to IJVS. Methods In December 2020, we performed a literature search on Pubmed/Medline and Scopus databases for original articles studying surgical and endovascular interventions used for intracranial hypertension in the setting of internal jugular vein stenosis. No date, patient population, or study type was excluded. Results All studies that included at least one case in which a surgical or endovascular intervention was used to treat IJVS were included. Selection criteria for patients varied, most commonly defined by identification of compression of the internal jugular vein. The 17 studies included in this review ranged from case reports to large single-center cohort studies. The most used surgical intervention was styloidectomy. Styloidectomy had an overall better outcome success rate (79%) than angioplasty/stenting (66%). No complications were recorded in any of the surgical cases analyzed. Outcome measures varied, but all studies recorded clinical symptoms of the patients. Conclusion Few current large cohort studies analyze surgical and endovascular interventions for patients with IJVS. Notably, the most common intervention is styloidectomy, followed by internal jugular vein stenting. By understanding the trends and experience of interventionalists and surgeons, more focused and larger studies can be performed to determine effective strategies with the best clinical outcomes.
- 14 July 2021
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 32 (8) , 1203-1208.e1
Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma with Intra-atrial Tumor Extension: Imaging Response and Oncologic Outcomes
- 14 July 2021
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 32 (8) , 1203-1208.e1
Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma with Intra-atrial Tumor Extension: Imaging Response and Oncologic Outcomes
- 1 February 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (2) , 292-294
Disrupting the Education Paradigm: An Opportunity to Advance Simulation Training in Radiology—Radiology In Training
Download as PowerPoint
- 1 February 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (2) , 292-294
Disrupting the Education Paradigm: An Opportunity to Advance Simulation Training in Radiology—Radiology In Training
Download as PowerPoint
- Open Access
- 1 January 2021
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 5 (4) , 235-243
Better Than You Think—Appropriate Use of Implantable Cardioverter-Defibrillators at a Single Academic Center: A Retrospective Review
Background: Implantable cardioverter-defibrillators (ICDs) can be life-saving devices, although they are expensive and may cause complications. In 2013, several professional societies published joint appropriate use criteria (AUC) assessing indications for ICD implantation. Data evaluating the clinical application of AUC are limited. Previous registry-based studies estimated that 22.5% of primary prevention ICD implantations were “non-evidence-based” implantations. On the basis of AUC, we aimed to determine the prevalence of “rarely appropriate” ICD implantation at our institution for comparison with previous estimates. Methods: We reviewed 286 patients who underwent ICD implantation between 2013 and 2016. Appropriateness of each ICD implantation was assessed by independent review and rated on the basis of AUC. Results: Of 286 ICD implantations, two independent reviewers found that 89.5% and 89.2%, respectively, were appropriate, 5.6% and 7.3% may be appropriate, and 1.8% and 2.1% were rarely appropriate. No AUC indication was found for 3.5% and 3.4% of ICD implantations, respectively. Secondary prevention ICD implantations were more likely rarely appropriate (2.6% vs. 1.2% and 3.6% vs. 1.1%) or unrated (6.0% vs. 1.2% and 2.7% vs. 0.6%). The reviewers found 3.5% and 3.4% of ICD implantations, respectively, were non-evidence-based implantations. The difference in rates between reviewers was not statistically significant. Conclusion: Compared with prior reports, our prevalence of rarely appropriate ICD implantation was very low. The high appropriate use rate could be explained by the fact that AUC are based on current clinical practice. The AUC could benefit from additional secondary prevention indications. Most importantly, clinical judgement and individualized care should determine which patients receive ICDs irrespective of guidelines or criteria.
- 1 January 2021
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 5 (4) , 235-243
Open AccessBetter Than You Think—Appropriate Use of Implantable Cardioverter-Defibrillators at a Single Academic Center: A Retrospective Review
Background: Implantable cardioverter-defibrillators (ICDs) can be life-saving devices, although they are expensive and may cause complications. In 2013, several professional societies published joint appropriate use criteria (AUC) assessing indications for ICD implantation. Data evaluating the clinical application of AUC are limited. Previous registry-based studies estimated that 22.5% of primary prevention ICD implantations were “non-evidence-based” implantations. On the basis of AUC, we aimed to determine the prevalence of “rarely appropriate” ICD implantation at our institution for comparison with previous estimates. Methods: We reviewed 286 patients who underwent ICD implantation between 2013 and 2016. Appropriateness of each ICD implantation was assessed by independent review and rated on the basis of AUC. Results: Of 286 ICD implantations, two independent reviewers found that 89.5% and 89.2%, respectively, were appropriate, 5.6% and 7.3% may be appropriate, and 1.8% and 2.1% were rarely appropriate. No AUC indication was found for 3.5% and 3.4% of ICD implantations, respectively. Secondary prevention ICD implantations were more likely rarely appropriate (2.6% vs. 1.2% and 3.6% vs. 1.1%) or unrated (6.0% vs. 1.2% and 2.7% vs. 0.6%). The reviewers found 3.5% and 3.4% of ICD implantations, respectively, were non-evidence-based implantations. The difference in rates between reviewers was not statistically significant. Conclusion: Compared with prior reports, our prevalence of rarely appropriate ICD implantation was very low. The high appropriate use rate could be explained by the fact that AUC are based on current clinical practice. The AUC could benefit from additional secondary prevention indications. Most importantly, clinical judgement and individualized care should determine which patients receive ICDs irrespective of guidelines or criteria.
- 19 November 2020
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 04 (04) , 358-364
Combination Therapies with Ablation: Immunoablation
Percutaneous ablation has been increasingly utilized as an alternative or adjunct to surgical resection of solid tumors. However, high rates of local recurrence and disease progression both with resection and ablation, particularly in patients with primary and metastatic liver malignancies, have limited further extension of overall survival. Systemic oncology treatment has progressed beyond traditional chemotherapeutic agents to immunotherapeutic agents that exert their effect by enhancing the body's immune response against cancer cells. The induction of necrotic cell death and the release of a large number of tumor antigens as a result of ablation have stimulated interest in combination therapy as a potential method of improving response to immunotherapy. This review focuses on the current scientific evidence for combination therapy of immuno-oncologic agents and locoregional ablation techniques.
- 19 November 2020
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 04 (04) , 358-364
Combination Therapies with Ablation: Immunoablation
Percutaneous ablation has been increasingly utilized as an alternative or adjunct to surgical resection of solid tumors. However, high rates of local recurrence and disease progression both with resection and ablation, particularly in patients with primary and metastatic liver malignancies, have limited further extension of overall survival. Systemic oncology treatment has progressed beyond traditional chemotherapeutic agents to immunotherapeutic agents that exert their effect by enhancing the body's immune response against cancer cells. The induction of necrotic cell death and the release of a large number of tumor antigens as a result of ablation have stimulated interest in combination therapy as a potential method of improving response to immunotherapy. This review focuses on the current scientific evidence for combination therapy of immuno-oncologic agents and locoregional ablation techniques.
- 1 August 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 296 (2) , 452-459
Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year Prospective Study and Comparison with Matched Cohorts from the National Cancer Database
This 10-year prospective observational study in patients with biopsy-proven renal cell carcinoma showed that percutaneous cryoablation was associated with a high disease-specific survival (94%) and... Background Percutaneous cryoablation (PCA) is an increasingly utilized treatment for stage I renal cell carcinoma (RCC), albeit without supportive level I evidence. Purpose Primary objective was to...
- 1 August 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 296 (2) , 452-459
Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year Prospective Study and Comparison with Matched Cohorts from the National Cancer Database
This 10-year prospective observational study in patients with biopsy-proven renal cell carcinoma showed that percutaneous cryoablation was associated with a high disease-specific survival (94%) and... Background Percutaneous cryoablation (PCA) is an increasingly utilized treatment for stage I renal cell carcinoma (RCC), albeit without supportive level I evidence. Purpose Primary objective was to...
- 17 February 2020
- Published by Elsevier in The Joint Commission Journal on Quality and Patient Safety
- Vol. 46 (6) , 359-364
Surgical Residents as Certified Bilingual Speakers: A Quality Improvement Initiative
- 17 February 2020
- Published by Elsevier in The Joint Commission Journal on Quality and Patient Safety
- Vol. 46 (6) , 359-364
Surgical Residents as Certified Bilingual Speakers: A Quality Improvement Initiative
- Open Access
- 5 July 2018
- Published by SAGE Publications in Journal of the Intensive Care Society
- Vol. 20 (3) , 277-280
A case of sinus pause induced by swallowing in the setting of olanzapine and guanfacine overdose
Olanzapine, a second-generation antipsychotic, is used in both adult and pediatric populations for schizophrenia, bipolar disorder, and depression and has been associated with autonomic dysregulation in the setting of overdose. Guanfacine is a sympatholytic drug used in the treatment of attention deficit hyperactivity disorder and has also been associated with autonomic dysfunction. We present a unique case of a 17-year-old male who overdosed on 340 mg of olanzapine and 189 mg of extended-release guanfacine with a previously unreported adverse event. Specifically, five days after ingestion, he developed a 5–8 s sinus pause every time he forcefully swallowed any beverage, suggestive of a vagal hypersensitivity reaction. The report will review the autonomic dysfunction of olanzapine and guanfacine and management of asymptomatic sinus pause in the critical care setting.
- 5 July 2018
- Published by SAGE Publications in Journal of the Intensive Care Society
- Vol. 20 (3) , 277-280
Open AccessA case of sinus pause induced by swallowing in the setting of olanzapine and guanfacine overdose
Olanzapine, a second-generation antipsychotic, is used in both adult and pediatric populations for schizophrenia, bipolar disorder, and depression and has been associated with autonomic dysregulation in the setting of overdose. Guanfacine is a sympatholytic drug used in the treatment of attention deficit hyperactivity disorder and has also been associated with autonomic dysfunction. We present a unique case of a 17-year-old male who overdosed on 340 mg of olanzapine and 189 mg of extended-release guanfacine with a previously unreported adverse event. Specifically, five days after ingestion, he developed a 5–8 s sinus pause every time he forcefully swallowed any beverage, suggestive of a vagal hypersensitivity reaction. The report will review the autonomic dysfunction of olanzapine and guanfacine and management of asymptomatic sinus pause in the critical care setting.